Baiyunshan Hanfang makes its debut at CPHI China 2026, joining you to discuss the new future of API internationalization.

2026/08/10 14:10:19 News

【Introduction】From June 16 to 18, the 24th CPHI China 2026 concluded successfully at the Shanghai New International Expo Center. This year’s event was themed “Pooling Strength for Collaborative Innovation, Smartly Pioneering the Future of Pharmaceuticals,” with an exhibition area exceeding 240,000 square meters. It brought together more than 3,600 exhibitors from around the world and over 110,000 professional visitors, focusing on cutting-edge technologies in the pharmaceutical industry and global market trends, while establishing a hub platform for exchange and cooperation across the entire industrial chain. Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a subsidiary of Guangyao Group—a Fortune Global 500 company—showcased its core products, engaged in face-to-face discussions with industry partners, explored new opportunities for collaboration, and jointly mapped out a new vision for the industry.

【Keywords】 Baiyunshan Hanfang, CPHI, active pharmaceutical ingredients

【Exhibition Hall Photo】

【Photo of Baiyunshan Hanfang Party Secretary and Chairman Yuan Cheng, Deputy General Manager Tang Shunzhi, and the marketing team】

During the exhibition, Baiyunshan Hanfang’s booth was bustling with visitors, attracting a steady stream of domestic and international business partners. Baiyunshan Hanfang Party Secretary and Chairman Yuan Cheng, along with Deputy General Manager Tang Shunzhi and the marketing team, warmly welcomed every guest with great enthusiasm, comprehensively showcasing the company’s strength and product appeal.

Exhibition Highlights

With years of dedicated expertise in the API field, Baiyunshan Hanfang has earned numerous international certifications and prestigious honors through rigorous quality control and continuous technological innovation: it holds ISO 14001 environmental management system certification and CNAS laboratory accreditation, and has been recognized as a “National Green Factory.” Its products have obtained international market approvals such as Mexico’s Cofepris and India’s DCGI, solidifying its global reputation with robust capabilities.

At the exhibition, the team engaged in in-depth discussions with domestic and international pharmaceutical companies and industry experts, focusing on key topics such as compliant API production, international market access, collaborative supply chain stability, and innovative R&D. By precisely addressing customers’ individual needs, they secured multiple cooperation intentions on-site, injecting fresh momentum into deepening global strategic partnerships and expanding their international market footprint.

【Customer Meetings/Group Photos Scroll】

Today, the global pharmaceutical industry is undergoing rapid transformation, ushering in a new phase of high-quality development for the API sector. Upholding the core values of “pioneering innovation, professionalism and pragmatism, and win-win cooperation,” Baiyunshan Hanfang will continue to deepen its expertise in the API field, increase R&D investment, and upgrade its quality management systems. It remains committed to aligning with international standards, strengthening global strategic partnerships, and expanding its international market presence. By promoting synergistic development between specialty APIs and innovative traditional Chinese medicines, Baiyunshan Hanfang aims to contribute Chinese strength to the high-quality growth of the global pharmaceutical industry with premium products and cutting-edge technology, writing a new chapter in the internationalization of Chinese API enterprises.

#CPHI #BaiyunshanHanfang